Who is sponsoring NCT00524225?

NCT00524225 is sponsored by Margaret Ragni.

What drugs are being tested in NCT00524225?

Interventions in NCT00524225: Neumega (Oprelvekin, Interleukin 11, IL-11).

What condition does NCT00524225 study?

NCT00524225 studies Von Willebrand Disease.

Is NCT00524225 still recruiting?

NCT00524225 is currently terminated. Last updated 2 June 2019.

Are results published for NCT00524225?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2019-06-02 · How we verify

NCT00524225

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase II Clinical Efficacy Trial of Recombinant Interleukin-11 (rhIL-11, Neumega) in Subjects With Type 1 Von Willebrand Disease Undergoing Surgery

Terminated Phase 2 Results posted Last updated 2 June 2019

What this trial tests

Phase 2 trial testing Neumega (Oprelvekin, Interleukin 11, IL-11) in Von Willebrand Disease in 3 participants. Terminated before completion.

Timeline

1 February 2008

Primary endpoint
1 June 2012

1 June 2012

Quick facts

Lead sponsor	Margaret Ragni
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	prevention
Enrollment	3
Start date	1 February 2008
Primary completion	1 June 2012
Estimated completion	1 June 2012
Sites	1 location across United States

Drugs / interventions tested

Neumega (Oprelvekin, Interleukin 11, IL-11) — full drug profile →

Conditions studied

Von Willebrand Disease — all drugs for Von Willebrand Disease →

Sponsor

Margaret Ragni — full company profile →

Who can join

18 and older, any sex, with Von Willebrand Disease. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Volume of Surgical Blood Loss
Time frame: 4 weeks
Hemostatic efficacy was measured by estimated blood loss (cc) during the surgical procedure.
Volume of Blood Transfusion
Time frame: 4 weeks
The volume of blood transfusion required (units of blood) after the surgical procedure.

Sponsor's own description

The purpose of this study is to determine the efficacy and safety of rhIL-11 when given subcutaneously in adults with type 1 von Willebrand disease undergoing elective surgery or major dental procedure. Efficacy will be measured by estimated blood loss, and frequency and severity of bleeding and transfusion requirement during and after surgery. Safety will be measured by the frequency of adverse events, including fever, headache, fatigue, myalgias, arthralgias, fluid retention, or edema.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Interleukin 11 therapy causes acute left ventricular dysfunction.
Sweeney M, O'Fee K, Villanueva-Hayes C, Rahman E, et al · · 2024 · cited 7× · PMID 39383190 · DOI 10.1093/cvr/cvae224

Verify or expand the search:

Other recruiting trials for Von Willebrand Disease

Currently open trials in the same condition.

NCT02932618 — A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Diseas · Phase 3 · recruiting

Other Margaret Ragni trials

Trials by the same sponsor.

NCT04303572 — The Hemophilia Inhibitor Eradication Trial · Phase 3 · terminated
NCT04303559 — The Hemophilia Inhibitor Prevention Trial · Phase 3 · terminated
NCT02606045 — Minimize Menorrhagia in Women With Von Willebrand Disease · Phase 3 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00524225 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Margaret Ragni
Last refreshed: 2 June 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00524225.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing